David Oh, MD, PhD
Principal Investigator
Assistant Professor In Residence
Dave received his AB in Biochemical Sciences from Harvard College in 2000, a combined MD/PhD as part of the Stanford Medical Scientist Training Program in 2011, and completed a residency in Internal Medicine and fellowship training in Hematology/Oncology at the University of California, San Francisco (UCSF) in 2017. He has been on the UCSF faculty since 2018. Dave is a board-certified Medical Oncologist focused on research efforts in the laboratory and clinic to understand and improve upon cancer immunotherapies, in particular genitourinary malignancies.
Clinically, he sees patients in the Cancer Immunotherapy Program where he is an attending physician, principal investigator, and co-investigator on early-phase trials testing novel immunotherapies in advanced solid tumors, with a focus on genitourinary malignancies. This includes high-risk modalities such as bispecific T cell engaging therapies, immune agonist antibodies, intratumoral immunotherapy, and adoptive cell therapies.
In the laboratory, he studies samples from prostate and bladder cancer patients treated with immunotherapy using unbiased platforms such as single-cell RNA sequencing and T cell receptor sequencing. The goal of this work is to discover and validate novel T cell populations and antigenic specificities that are responsible for anti-tumor efficacy as well as immune-related adverse events (IRAEs) resulting from treatment.
Yimin Shi, PhD
Specialist
Jun Yan (Joshua) He, BA
SRA 1
Hai Yang, MS
Senior Statistician (joint with Larry Fong)
Zhenghua Fan, PhD
Post-doctoral Fellow (joint with Larry Fong)